Technical Analysis for ENZ - Enzo Biochem, Inc.

Grade Last Price % Change Price Change
grade C 3.51 -1.68% -0.06
ENZ closed down 1.68 percent on Friday, September 20, 2019, on 1.95 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Down
See historical ENZ trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
200 DMA Support Bullish 0.00%
20 DMA Support Bullish 0.00%
50 DMA Support Bullish -1.68%
Pocket Pivot Bullish Swing Setup -1.68%
50 DMA Support Bullish -0.57%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.57%
Upper Bollinger Band Walk Strength -0.57%
Down 3 Days in a Row Weakness -0.57%
50 DMA Support Bullish -1.96%

Older signals for ENZ ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Biotechnology Cancer Life Sciences Diabetes Antibodies Obesity Drug Development Gene Expression Neurological Disorders Genetic Engineering Cardiovascular Disease Two River Metabolic Diseases Medical Laboratory Medical Diagnosis Endocrine Disorders
Is ENZ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.55
52 Week Low 2.32
Average Volume 173,856
200-Day Moving Average 3.3871
50-Day Moving Average 3.522
20-Day Moving Average 3.3725
10-Day Moving Average 3.547
Average True Range 0.2028
ADX 16.11
+DI 19.8351
-DI 20.0042
Chandelier Exit (Long, 3 ATRs ) 3.1916
Chandelier Exit (Short, 3 ATRs ) 3.5684
Upper Bollinger Band 3.7761
Lower Bollinger Band 2.9689
Percent B (%b) 0.67
BandWidth 23.934766
MACD Line 0.0433
MACD Signal Line 0.0126
MACD Histogram 0.0307
Fundamentals Value
Market Cap 163.38 Million
Num Shares 46.5 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -70.20
Price-to-Sales 4.40
Price-to-Book 5.34
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.98
Resistance 3 (R3) 3.96 3.80 3.90
Resistance 2 (R2) 3.80 3.68 3.80 3.87
Resistance 1 (R1) 3.65 3.61 3.57 3.67 3.85
Pivot Point 3.49 3.49 3.45 3.49 3.49
Support 1 (S1) 3.34 3.37 3.26 3.36 3.17
Support 2 (S2) 3.18 3.30 3.18 3.15
Support 3 (S3) 3.03 3.18 3.12
Support 4 (S4) 3.05